Search

Your search keyword '"Erdem-Eraslan, Lale"' showing total 29 results
Start Over Author "Erdem-Eraslan, Lale"
29 results on '"Erdem-Eraslan, Lale"'

3. Added value of drug-laboratory test interaction alerts in test result authorisation

Author

van Balveren, Jasmijn A., Verboeket-van de Venne, Wilhelmine P.H.G., Doggen, Carine J.M., Erdem-Eraslan, Lale, de Graaf, Albert J., Krabbe, Johannes G., Musson, Ruben E.A., Oosterhuis, Wytze P., De Rijke, Yolanda B., van der Sijs, Heleen, Tintu, Andrei N., Verheul, Rolf J., Hoedemakers, Rein M.J., Kusters, Ron, Clinical Chemistry, Pharmacy, Health Technology & Services Research, and TechMed Centre

Subjects
Laboratory test, Patient safety, Drug-laboratory test interaction (DLTI), Biochemistry (medical), Clinical Biochemistry, Humans, Drug Interactions, General Medicine, Clinical Decision Support System (CDSS), Decision Support Systems, Clinical, NLA, Diagnostic error
Published
2022

4. Supplementary Table 2 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure legends from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 4 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 2 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 3 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S13 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Table S1 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

14. Data from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure Legends from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

17. Real-time monitoring of drug laboratory test interactions: a proof of concept

Author

van Balveren, Jasmijn A., primary, Verboeket-van de Venne, Wilhelmine P.H.G., additional, Doggen, Carine J.M., additional, Erdem-Eraslan, Lale, additional, de Graaf, Albert J., additional, Krabbe, Johannes G., additional, Musson, Ruben E.A., additional, Oosterhuis, Wytze P., additional, de Rijke, Yolanda B., additional, van der Sijs, Heleen, additional, Tintu, Andrei N., additional, Verheul, Rolf J., additional, Hoedemakers, Rein M.J., additional, and Kusters, Ron, additional

Published
2021
Full Text
View/download PDF

18. Clinical usefulness of drug-laboratory test interaction alerts: a multicentre survey

Author

van Balveren, Jasmijn A., primary, Verboeket-van de Venne, Wilhelmine P. H. G., additional, Doggen, Carine J. M., additional, Cornelissen, Anne S., additional, Erdem-Eraslan, Lale, additional, de Graaf, Albert J., additional, Krabbe, Johannes G., additional, Musson, Ruben E. A., additional, Oosterhuis, Wytze P., additional, de Rijke, Yolanda B., additional, van der Sijs, Heleen, additional, Tintu, Andrei N., additional, Verheul, Rolf J., additional, Hoedemakers, Rein M. J., additional, and Kusters, Ron, additional

Published
2021
Full Text
View/download PDF

19. Real-time monitoring of drug laboratory test interactions: a proof of concept.

Author

van Balveren, Jasmijn A., Verboeket-van de Venne, Wilhelmine P.H.G., Doggen, Carine J.M., Erdem-Eraslan, Lale, de Graaf, Albert J., Krabbe, Johannes G., Musson, Ruben E.A., Oosterhuis, Wytze P., de Rijke, Yolanda B., van der Sijs, Heleen, Tintu, Andrei N., Verheul, Rolf J., Hoedemakers, Rein M.J., and Kusters, Ron

Subjects
DRUG monitoring, DECISION support systems, PROOF of concept, CHEMICAL laboratories, MEDICAL specialties & specialists
Abstract

For the correct interpretation of test results, it is important to be aware of drug-laboratory test interactions (DLTIs). If DLTIs are not taken into account by clinicians, erroneous interpretation of test results may lead to a delayed or incorrect diagnosis, unnecessary diagnostic testing or therapy with possible harm for patients. A DLTI alert accompanying a laboratory test result could be a solution. The aim of this study was to test a multicentre proof of concept of an electronic clinical decision support system (CDSS) for real-time monitoring of DLTIs. CDSS was implemented in three Dutch hospitals. So-called 'clinical rules' were programmed to alert medical specialists for possible DLTIs based on laboratory test results outside the reference range in combination with prescribed drugs. A selection of interactions from the DLTI database of the Dutch society of clinical chemistry and laboratory medicine were integrated in 43 clinical rules, including 24 tests and 25 drugs. During the period of one month all generated DTLI alerts were registered in the laboratory information system. Approximately 65 DLTI alerts per day were detected in each hospital. Most DLTI alerts were generated in patients from the internal medicine and intensive care departments. The most frequently reported DLTI alerts were potassium-proton pump inhibitors (16%), potassium-beta blockers (11%) and creatine kinase-statins (11%). This study shows that it is possible to alert for potential DLTIs in real-time with a CDSS. The CDSS was successfully implemented in three hospitals. Further research must reveal its usefulness in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

20. Diagnostic error as a result of drug-laboratory test interactions

Author

van Balveren, Jasmijn A., primary, Verboeket-van de Venne, Wilhelmine P.H.G., additional, Erdem-Eraslan, Lale, additional, de Graaf, Albert J., additional, Loot, Annemarieke E., additional, Musson, Ruben E.A., additional, Oosterhuis, Wytze P., additional, Schuijt, Martin P., additional, van der Sijs, Heleen, additional, Verheul, Rolf J., additional, de Wolf, Holger K., additional, Kusters, Ron, additional, and Hoedemakers, Rein M.J., additional

Published
2019
Full Text
View/download PDF

23. Impact of interactions between drugs and laboratory test results on diagnostic test interpretation – a systematic review.

Author

van Balveren, Jasmijn A., Verboeket-van de Venne, Wilhelmine P.H.G., Erdem-Eraslan, Lale, de Graaf, Albert J., Loot, Annemarieke E., Musson, Ruben E.A., Oosterhuis, Wytze P., Schuijt, Martin P., van der Sijs, Heleen, Verheul, Rolf J., de Wolf, Holger K., Kusters, Ron, and Hoedemakers, Rein M.J.

Subjects
CLINICAL pathology, ROUTINE diagnostic tests, SYSTEMATIC reviews, PHARMACISTS, PHYSICIANS
Abstract

Intake of drugs may influence the interpretation of laboratory test results. Knowledge and correct interpretation of possible drug-laboratory test interactions (DLTIs) is important for physicians, pharmacists and laboratory specialists. Laboratory results may be affected by analytical or physiological effects of medication. Failure to take into account the possible unintended influence of drug use on a laboratory test result may lead to incorrect diagnosis, incorrect treatment and unnecessary follow-up. The aim of this review is to give an overview of the literature investigating the clinical impact and use of DLTI decision support systems on laboratory test interpretation. Particular interactions were reported in a large number of articles, but they were fragmentarily described and some papers even reported contradictory findings. To provide an overview of information that clinicians and laboratory staff need to interpret test results, DLTI databases have been made by several groups. In a literature search, only four relevant studies have been found on DLTI decision support applications for laboratory test interpretation in clinical practice. These studies show a potential benefit of automated DLTI messages to physicians for the correct interpretation of laboratory test results. Physicians reported 30–100% usefulness of DLTI messages. In one study 74% of physicians sometimes even refrained from further additional examination. The benefit of decision support increases when a refined set of clinical rules is determined in cooperation with health care professionals. The prevalence of DLTIs is high in a broad range of combinations of laboratory tests and drugs and these frequently remain unrecognized. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

24. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., additional, Hoogstrate, Youri, additional, Naz-Khan, Hina, additional, Stubbs, Andrew, additional, van der Spek, Peter, additional, Böttcher, René, additional, Gao, Ya, additional, de Wit, Maurice, additional, Taal, Walter, additional, Oosterkamp, Hendrika M., additional, Walenkamp, Annemiek, additional, Beerepoot, Laurens V., additional, Hanse, Monique C.J., additional, Buter, Jan, additional, Honkoop, Aafke H., additional, van der Holt, Bronno, additional, Vernhout, René M., additional, Smitt, Peter A.E. Sillevis, additional, Kros, Johan M., additional, and French, Pim J., additional

Published
2016
Full Text
View/download PDF

25. MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, additional, Idbaih, Ahmed, additional, de Rooi, Johan, additional, Eilers, Paul H.C., additional, Spliet, Wim G.M., additional, den Dunnen, Wilfred F.A., additional, Tijssen, Cees, additional, Wesseling, Pieter, additional, Sillevis Smitt, Peter A.E., additional, Kros, Johan M., additional, Gorlia, Thierry, additional, and French, Pim J., additional

Published
2013
Full Text
View/download PDF

27. Abstract 642: A hypermethylated phenotype as predictive marker for response to PCV in anaplastic oligodendrogliomas. A report from EORTC study 26951.

Author

French, Pim J., primary, Erdem-Eraslan, Lale, additional, Idbaih, Ahmed, additional, Spliet, Wim, additional, den Dunnen, Wilfred, additional, Teepen, Johannes L., additional, Wesseling, Pieter, additional, Sillevis Smitt, Peter A., additional, Kros, Johan M., additional, Gorlia, Thierry, additional, and van den Bent, Martin, additional

Published
2013
Full Text
View/download PDF

28. Intrinsic Molecular Subtypes of Glioma Are Prognostic and Predict Benefit From Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Combination With Other Prognostic Factors in Anaplastic Oligodendroglial Brain Tumors: A Report From EORTC Study 26951

Author

Erdem-Eraslan, Lale, primary, Gravendeel, Lonneke A., additional, de Rooi, Johan, additional, Eilers, Paul H.C., additional, Idbaih, Ahmed, additional, Spliet, Wim G.M., additional, den Dunnen, Wilfred F.A., additional, Teepen, Johannes L., additional, Wesseling, Pieter, additional, Sillevis Smitt, Peter A.E., additional, Kros, Johan M., additional, Gorlia, Thierry, additional, van den Bent, Martin J., additional, and French, Pim J., additional

Published
2013
Full Text
View/download PDF

29. Inter‐individual variability in phospholipid‐dependent interference of C‐reactive protein on activated partial thromboplastin time.

Author

Erdem‐Eraslan, Lale, Hens, Jacques J. H., van Rossum, André P., Frasa, Marieke A. M., and Keuren, Jeffrey F. W.

Subjects
*C-reactive protein, *PARTIAL thromboplastin time, *PHOSPHOLIPIDS, *CLINICAL trials, *THROMBOPLASTIN
Abstract

The article highlights the study of C-reactive protein (CRP) in vitro interferes with commonly used activated partial thromboplastin time (aPTT) assays. Topics discussed include information on risk factors associated with CRP interfernece involves unnecessary plasma transfusions and postponement of surgery; information on the aPTT assays used STA Cephascreen and Dade Actin FS; and study reveals that prolongation of the aPTT coagulation times by CRP is phospholipids dose-dependent.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results